Eman T. Al-Antary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eman T. Al-Antary has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abdalla Awidi
Cell Therapy Center, The University of Jordan, Amman 11942, Jordan
1 shared publication - Amenah Al Abdullah
Department of Radiology, School of Medicine, University of Jordan, Amman, Jordan
1 shared publication Avanti Gupte
Division of Hematology/Oncology, Children’s Hospital of Michigan
1 shared publication- Dana Alhattab
Cell Therapy Center, The University of Jordan, Amman, Jordan
1 shared publication - Dima Hmaid
Department of Radiology, School of Medicine, University of Jordan, Amman, Jordan
1 shared publication - Esraa Al-Jabbari
Department of Radiology, School of Medicine, University of Jordan, Amman, Jordan
1 shared publication
Latest Publications
- Open Access
- 24 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1875354
Case Report: Primary hemophagocytic lymphohistiocytosis with a homozygous PRF1 variant: a case suggesting early immunoporosis and an expanded phenotypic spectrum
Familial HLH is an autosomal recessive condition characterized by mutations in genes responsible for the secretory lysosome-dependent exocytosis pathway. Its diagnosis is often challenging to complex clinical presentation, and prompt treatment is essential to avoid fatal outcomes. We describe a novel PRF1 mutation variant p.Y296C c.887 A>G in a pediatric patient with familial HLH (FHL2), which has not yet been reported in the literature to be associated with primary HLH. In this case, we also hypothesize that the phenomenon of immunoporosis contributed to the significant skeletal muscle findings reported in our patient.
- 24 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1875354
Open AccessCase Report: Primary hemophagocytic lymphohistiocytosis with a homozygous PRF1 variant: a case suggesting early immunoporosis and an expanded phenotypic spectrum
Familial HLH is an autosomal recessive condition characterized by mutations in genes responsible for the secretory lysosome-dependent exocytosis pathway. Its diagnosis is often challenging to complex clinical presentation, and prompt treatment is essential to avoid fatal outcomes. We describe a novel PRF1 mutation variant p.Y296C c.887 A>G in a pediatric patient with familial HLH (FHL2), which has not yet been reported in the literature to be associated with primary HLH. In this case, we also hypothesize that the phenomenon of immunoporosis contributed to the significant skeletal muscle findings reported in our patient.
- Open Access
- 12 December 2017
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 12 (1) , 1-6
Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study
Knee osteoarthritis (KOA) is a major health problem especially in the aging population. There is a need for safe treatment that restores the cartilage and reduces the symptoms. The use of stem cells is emerging as a possible option for the moderate and severe cases. This study aimed at testing the safety of autologous bone marrow mesenchymal stem cells (BM-MSCs) expanded in vitro when given intra-articularly to patients with stage II and III KOA. As a secondary end point, the study tested the ability of these cells to relieve symptoms and restore the knee cartilage in these patients as judged by normalized knee injury and Osteoarthritis Outcome Score (KOOS) and by magnetic resonance imaging (MRI). Thirteen patients with a mean age of 50 years suffering from KOA stages II and III were given two doses of BM-MSCs 1 month apart totaling 61 × 106 ± 0.6 × 106 by intra-articular injection in a phase I prospective clinical trial. Each patient was followed for a minimum of 24 months for any adverse events and for clinical outcome using normalized KOOS. Cartilage thickness was assessed by quantitative MRI T2 at 12 months of follow-up. No severe adverse events were reported up to 24 months follow-up. Normalized KOOS improved significantly. Mean knee cartilage thickness measured by MRI improved significantly. BM-MSCs given intra-articularly are safe in knee osteoarthrosis. Despite the limited number of patients in this study, the procedure described significantly improved the KOOS and knee cartilage thickness, indicating that they may enhance the functional outcome as well as the structural component. ClinicalTrials.gov, NCT02118519
- 12 December 2017
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 12 (1) , 1-6
Open AccessIntra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study
Knee osteoarthritis (KOA) is a major health problem especially in the aging population. There is a need for safe treatment that restores the cartilage and reduces the symptoms. The use of stem cells is emerging as a possible option for the moderate and severe cases. This study aimed at testing the safety of autologous bone marrow mesenchymal stem cells (BM-MSCs) expanded in vitro when given intra-articularly to patients with stage II and III KOA. As a secondary end point, the study tested the ability of these cells to relieve symptoms and restore the knee cartilage in these patients as judged by normalized knee injury and Osteoarthritis Outcome Score (KOOS) and by magnetic resonance imaging (MRI). Thirteen patients with a mean age of 50 years suffering from KOA stages II and III were given two doses of BM-MSCs 1 month apart totaling 61 × 106 ± 0.6 × 106 by intra-articular injection in a phase I prospective clinical trial. Each patient was followed for a minimum of 24 months for any adverse events and for clinical outcome using normalized KOOS. Cartilage thickness was assessed by quantitative MRI T2 at 12 months of follow-up. No severe adverse events were reported up to 24 months follow-up. Normalized KOOS improved significantly. Mean knee cartilage thickness measured by MRI improved significantly. BM-MSCs given intra-articularly are safe in knee osteoarthrosis. Despite the limited number of patients in this study, the procedure described significantly improved the KOOS and knee cartilage thickness, indicating that they may enhance the functional outcome as well as the structural component. ClinicalTrials.gov, NCT02118519